Published in Blood Weekly, December 20th, 2001
"We are pleased that the FDA has approved our application to market daunorubicin for acute leukemias," said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. "The addition of daunorubicin further enhances our marketed portfolio, which contains Nipent and mitomycin. FDA approval once again demonstrates our ability to integrate all of our capabilities, from start to finish.
SuperGen's direct oncology sales force will be responsible for marketing daunorubicin to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.